@prefix this: . @prefix rdfs: . @prefix xsd: . @prefix sio: . @prefix ncit: . @prefix lld: . @prefix miriam-gene: . @prefix miriam-pubmed: . @prefix eco: . @prefix wi: . @prefix prov: . @prefix pav: . @prefix prv: . @prefix dcterms: . @prefix np: . @prefix dgn-np: . @prefix dgn-gda: . @prefix dgn-void: . dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_head { this: np:hasAssertion dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_assertion; np:hasProvenance dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_provenance; np:hasPublicationInfo dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_publicationInfo; a np:Nanopublication . dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_assertion a np:Assertion . dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_provenance a np:Provenance . dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_publicationInfo a np:PublicationInfo . } dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_assertion { miriam-gene:7096 a ncit:C16612 . lld:C0025202 a ncit:C7057 . dgn-gda:DGN41295ed41103e1f5a0f08ee43201bed6 sio:SIO_000628 miriam-gene:7096, lld:C0025202; a sio:SIO_001121 . } dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_provenance { dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_assertion dcterms:description "[We noted: (a) a significant difference in the frequency of A11 (20.5% versus 10.2%; P < 0.05) allele between melanoma patients and the North American Caucasian population; (b) a significantly higher frequency of A11 phenotype among responders (40.5%) than in the melanoma patient population (20.5%; P < 0.01), which was even more obvious among patients responding to TIL therapy (47.4% versus 22.1%; P < 0.05); within TIL patients, responders also had an increased frequency of A19 (42.1% versus 25.6%; P < 0.05); (c) a correlation between the number of TILs received and response rate (P < 0.005); and (d) an association between DR4 haplotype and decreased tolerance to IL-2 among the patients receiving TILs (P = 0.01).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en; wi:evidence dgn-void:source_evidence_literature; sio:SIO_000772 miriam-pubmed:1423301; prov:wasDerivedFrom dgn-void:befree-20150227; prov:wasGeneratedBy eco:ECO_0000203 . dgn-void:befree-20150227 pav:importedOn "2015-02-27"^^xsd:date . dgn-void:source_evidence_literature a eco:ECO_0000212; rdfs:comment "Gene-disease associations inferred from text-mining the literature."@en; rdfs:label "DisGeNET evidence - LITERATURE"@en . } dgn-np:NP739821.RAlCLiWEjAFnWKYY79EibEUjC0gSH1_pnYpUkSG0dVsS0130_publicationInfo { this: dcterms:created "2015-08-25T14:45:06+02:00"^^xsd:dateTime; dcterms:rights ; dcterms:rightsHolder dgn-void:IBIGroup; dcterms:subject sio:SIO_000983; prv:usedData dgn-void:disgenetv3.0rdf; pav:authoredBy , , , , ; pav:createdBy ; pav:version "v3.0.0.0" . dgn-void:disgenetv3.0rdf pav:version "v3.0.0" . }